Search
Now showing items 1-2 of 2
The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial
Background: Mammary Prevention.3 (MAP.3) was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ...
Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women
Background: In the Mammary Prevention.3 (MAP.3) randomized placebo-controlled trial of exemestane, postmenopausal women experienced a loss in bone mineral density (BMD). UGT2B17 facilitates excretion of androgens and ...